Subramani R, Datta Manjula, Swaminathan S
National Institute for Research in Tuberculosis, Chennai, India.
Former Deputy Director, National Institute for Research in Tuberculosis, Chennai, India.
Indian J Tuberc. 2015 Oct;62(4):226-9. doi: 10.1016/j.ijtb.2015.08.002. Epub 2016 Jan 23.
The protective efficacy of BCG was studied for over 15 years, from 1968, in South India. A secondary analysis of data was performed to investigate the relationship between Bacille Calmette-Guérin (BCG) and tuberculosis (TB) disease and between BCG and positive tuberculin skin test for different time periods among children aged less than 10 years. A randomized controlled trial was conducted, where 281,161 persons were allocated to receive BCG 0.1mg, BCG 0.01mg or placebo. Tuberculin skin test was performed at baseline and at 4 years after BCG vaccination. Surveys were conducted every 2.5 years to detect all new cases of culture-positive/smear-positive TB occurring in the community over a 15-year period. Relative risk (RR) was obtained from the ratio of incidence among the vaccinated and the placebo groups. Among those children vaccinated with 0.1mg of BCG, the RR for TB was 0.56 (95% CI: 0.32-0.87, P=0.01) at 12.5 years but increased to 0.73 later. Similar pattern was seen with 0.01mg. The increase in the number of skin test positives with 0.1mg of BCG was 57.8%, 49.4% and 34% for cut-off points at ≥10mm, ≥12mm and ≥15mm, respectively. The study suggests that the effect of BCG may decrease since vaccination and the tuberculin positive was higher at post-vaccination test period due to BCG.
1968年起,在印度南部对卡介苗(BCG)的保护效力进行了超过15年的研究。对数据进行二次分析,以调查卡介苗与结核病(TB)之间的关系,以及在10岁以下儿童的不同时间段内卡介苗与结核菌素皮肤试验阳性之间的关系。开展了一项随机对照试验,将281,161人分配接受0.1mg卡介苗、0.01mg卡介苗或安慰剂。在基线和卡介苗接种后4年进行结核菌素皮肤试验。每2.5年进行一次调查,以检测15年内社区中所有新出现的培养阳性/涂片阳性结核病病例。相对风险(RR)通过接种组与安慰剂组的发病率之比获得。在接种0.1mg卡介苗的儿童中,12.5岁时结核病的RR为0.56(95%CI:0.32 - 0.87,P = 0.01),但后来增至0.73。0.01mg卡介苗的情况类似。对于0.1mg卡介苗,皮肤试验阳性人数在截断点≥10mm、≥12mm和≥15mm时分别增加了57.8%、49.4%和34%。该研究表明,卡介苗的效果自接种后可能会降低,且由于卡介苗的作用,接种后试验期的结核菌素阳性率更高。